Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?
Alder Obtains First Milestone Under BMS Deal, Advances Own Program In Cancer Supportive Care
Privately held biotech earns $15 million as Bristol Myers Squibb readies interleukin-6 inhibitor for Phase IIb dose-ranging trial in rheumatoid arthritis.
More from Archive
• By
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
• By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
• By
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
• By
Only Bausch Health’s Xifaxan may have had a lower initial offer among the 15 drugs in the current Medicare price negotiation round, researchers at the University of Washington and the University of California, San Diego, projected.
• By
Sponsors should consider whether their TV commercials contain the same number of scene changes during the major statement as ads that received a violation letter.
• By
One clear message from a US FDA listening session on leveraging knowledge across cell and gene therapy products is sponsors want more guidance on how the FDA’s new platform therapy pathway will function.